Skin Cancer Unit, Dermatology Department, Hôpital Saint André, Bordeaux, France.
Ann Oncol. 2012 Apr;23(4):1074-80. doi: 10.1093/annonc/mdr318. Epub 2011 Jul 12.
The treatment of stage I Merkel cell carcinoma (MCC) usually includes wide local excision (WLE) combined with irradiation of the tumor bed (ITB). No randomized study has ever been conducted in MCC. The purpose of this study was to assess the efficacy and safety of prophylactic adjuvant radiotherapy on the regional nodes.
In this randomized open controlled study, patients for a stage I MCC treated by WLE and ITB were randomly assigned to regional adjuvant radiotherapy versus observation. Overall survival (OS) and probability of regional recurrence (PRR) were primary end points. Progression-free survival (PFS) and tolerance of irradiation were secondary end points.
Eighty-three patients were included before premature interruption of the trial, due to a drop in the recruitment mainly due to the introduction of the sentinel node dissection in the management of MCC. No significant improvement in OS (P = 0.989) or PFS (P = 0.4) could be demonstrated after regional irradiation, which, however, significantly reduced the PRR (P = 0.007) with 16.7% regional recurrence rate in the observation arm versus 0% in the treatment arm. The treatment was well tolerated.
The adjuvant regional irradiation significantly decreased the PRR in MCC, but benefit in survival could not be demonstrated.
I 期 Merkel 细胞癌(MCC)的治疗通常包括广泛局部切除(WLE)联合肿瘤床照射(ITB)。MCC 从未进行过随机研究。本研究旨在评估预防性辅助放疗对区域淋巴结的疗效和安全性。
在这项随机开放对照研究中,接受 WLE 和 ITB 治疗的 I 期 MCC 患者被随机分配至区域辅助放疗组或观察组。总生存期(OS)和区域复发率(PRR)是主要终点。无进展生存期(PFS)和放疗耐受性是次要终点。
由于招募人数下降,试验提前中断,共纳入 83 例患者,主要原因是前哨淋巴结活检在 MCC 治疗管理中的应用。区域照射后 OS(P = 0.989)或 PFS(P = 0.4)无显著改善,但显著降低了 PRR(P = 0.007),观察组的区域复发率为 16.7%,而治疗组为 0%。治疗耐受性良好。
辅助区域放疗显著降低了 MCC 的 PRR,但不能证明生存获益。